Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASCO 2023 - Breast Cancer
SABCS 2022
ASCO 2022 - Wrap Up
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Podcasts
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
JHOP
Print Edition
JHOP
Weekly e‑Newsletter
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
JHOP
's
Privacy Policy
, and
JHOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASCO 2023 - Breast Cancer
SABCS 2022
ASCO 2022 - Wrap Up
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Podcasts
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
JHOP - August 2022 Vol 12, No 4
Editorial
Case Reports
Original Article
Practical Issues in Pharmacy Management
FDA Oncology Update
ASCO Highlights
Editorial
Optimal Sequencing of Cancer Treatments an Increasingly Important Question
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Read More
Case Reports
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
Carrie L. Barnhart, PharmD, BCOP, and David F. Christianson, MD
Read More
Original Article
Comparing the Impact of Abiraterone and Enzalutamide Sequencing on Progression-Free Survival in Veterans with Metastatic Castration-Resistant Prostate Cancer
Nicholas J. Newman, PharmD; Sara E. Gordon, PharmD, BCOP; Charles J. Nock, MD; Christopher J. Burant, PhD; Candice M. Wenzell, PharmD, BCOP
Read More
The Link Between Hypoalbuminemia and Oral Tyrosine Kinase Inhibitor Adverse Events in Adults with Malignant Solid Tumors
Jessica Marini, PharmD, BCOP; Bailey Bass Hammond, PharmD; Jacob Rennebaum, PharmD; Erin Weeda, PharmD, BCPS; Jagoda Misniakiewicz, PharmD; Amy Sion, PharmD, BCOP
Read More
Safety and Efficacy of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients with Cancer and Baseline Renal Dysfunction
Emily H. Hsu, PharmD, and Ryan Beechinor, PharmD, BCPS, BCOP
Read More
Practical Issues in Pharmacy Management
Sterility of Single-Use Vials When Using a Closed-System Transfer Device
Joan Antoni Schoenenberger-Arnaiz, PharmD, PhD; Maria Nevot-Blanc, PharmD; Merce Garcia-Gonzalez, PharmD; Mireia Martinez-Sogues, PharmD; Aida Moroba-Estor; Laura Rumi-Carrera, PharmD; Jason Battle, BS
Read More
FDA Oncology Update
Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor
Read More
Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma
Read More
Tafinlar plus Mekinist First Tumor Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation
Read More
Online Only
FDA Issues New Warning for Copiktra About Increased Risks for Serious Side Effects and Mortality
Read More
Online Only
Talquetamab, First-in-Class Bispecific Monoclonal Antibody, Granted Breakthrough Therapy by the FDA for Relapsed or Refractory Multiple Myeloma
Read More
ASCO Highlights
Meeting Highlights
Online Only
PD-1 Inhibition with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer
Read More
Meeting Highlights
Online Only
Black Patients with Cancer and COVID-19 More Likely Than White Patients to Have Therapy Disruptions
Read More
Meeting Highlights
Online Only
Trastuzumab Deruxtecan a New Standard for Patients with HER2-Low Metastatic Breast Cancer
Read More
Meeting Highlights
Online Only
Patients Aged ≥55 Years with Luminal A Breast Cancer Can Safely Avoid Radiation
Read More
Meeting Highlights
Online Only
ASCO Highlights Innovation as Key to Equitable Cancer Care
Read More
Privacy policy
Terms of Use
Home
About
Subscribe
Advertise
Contact Us
© Amplity Health. All rights reserved.